SEVERE DE NOVO PUSTULAR PSORIASIFORM IMMUNE-RELATED ADVERSE EVENT ASSOCIATED WITH NIVOLUMAB TREATMENT FOR METASTATIC ESOPHAGEAL ADENOCARCINOMA.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of cutaneous pathology"
DOI: 10.1111/cup.14185
Abstract: Breakthrough targeted therapies have produced significant improvements in survival for cancer patients, but have a propensity to cause cutaneous immune-related adverse events (irAEs). Psoriasiform irAEs, representing about 4% of dermatologic toxicities associated with immune checkpoint… read more here.
Keywords: ici therapy; immune related; psoriasiform; pustular psoriasiform ... See more keywords